18th International European AIDS Conference (EACS 2021)

27–30 October 2021, hybrid, London

Introduction

The 18th International European AIDS Conference (EACS 2021) ran from 27-30 October 2021 as a hybrid conference.

EACS are to be congratulated for taking this decision.

Approximately a quarter of the more than 3000 delegates attended the ExCel Centre in London, reconnecting for the first time since COVID-19 with interactions that can only come from face-to-face meetings – many commenting on how important this felt.

Other delegates were able to watch all the same sessions simultaneously as a live virtual meeting – with instant access to all content. Many of the sessions were also simultaneously translated into Russian.

This means that the conference immediately became available online for delegates.

The programme and abstract book from the meeting are available as open access, but other resources are more complicated, with webcasts behind a paywall.

• https://eacs2021.abstractserver.com/program (programme)
• https://onlinelibrary.wiley.com/toc/14681293/2021/22/S3 (PDF abstract book)
• https://eposters-eacs2021.medicalcongress.online (ePosters)
• https://europeanaidsconference.eacs.cyim.com (webcasts – needs EACS membership – from €30 for a year)

Abstracts can also be accessed through the online programme (first link above). For oral sessions this involves click on the day of the presentation and for posters this is through clicking the two elibrary listings in the programme (for Thursday and Friday).

Reports in this issue of HTB are below.

• Lenacapavir: drug resistance in treatment experienced participants
• Implications of historical M184V on use of dual dolutegravir/lamivudine ART
• Stopping long-acting cabotegravir/rilpivirine: 1 in 5 trial participants don’t restart oral ART within eight weeks
• Islatravir plus doravirine dual ART: 144 week follow-up from phase 2 study
• HIV-specific mental health services across the EU

Other reports from EACS 2021.